PD-1xVEGFxIL-7 multispecific antibody

PD-1xVEGFxIL-7 multispecific antibody is a preclinical trispecific immunocytokine candidate developed by Zymeworks. It is designed to simultaneously target programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF) while delivering an engineered, attenuated, and masked interleukin-7 (IL-7) cytokine. This design restricts IL-7 signaling primarily to PD-1-positive T cells, minimizing systemic activation of bystander T cells and enhancing the durability of anti-tumor immune responses. The VEGF-binding domain also acts as a mask for the IL-7 component, and complexing with VEGF further enhances PD-1 blockade and IL-7 potency. The candidate is being investigated for the treatment of multiple solid tumor indications.